- PR Newswire•1 hour agoRegeneron and Sanofi Present Positive Phase 3 Investigational Data for Praluent® (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016
TARRYTOWN, N.Y. and PARIS, Aug. 29, 2016 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced detailed positive results from ODYSSEY ESCAPE, a Phase 3 trial which evaluated Praluent® (alirocumab) Injection in patients with an inherited form of high cholesterol known as heterozygous familial hypercholesterolemia (HeFH) who require regular weekly or bi-weekly apheresis treatment. The trial demonstrated that adding Praluent to existing therapy reduced LDL cholesterol by approximately 50 percent from baseline (compared to 2 percent increase for placebo). Praluent significantly reduced the need for apheresis treatment by 75 percent compared to placebo (p less than 0.0001), the primary endpoint of the study.
- Motley Fool•2 days ago
PCSK-9 inhibitors lowered LDL-C by roughly 60% in clinical trials, but do their costs far outweigh their benefits?
- Investor's Business Daily•2 days ago
Week in review: Fed chief Janet Yellen said the rate hike case is stronger. Mylan's EpiPen price hike outrage roiled drug stocks. Best Buy soared as dollar stores dived.
NYSE - NYSE Real Time Price. Currency in USD
|Bid||38.60 x 400|
|Ask||38.92 x 100|
|Day's Range||38.51 - 39.21|
|52wk Range||37.41 - 51.88|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||21.26|
|Avg Vol (3m)||2,350,136|
|Dividend & Yield||1.66 (4.29%)|